Investigation of the prevelance of endometriosis in patients with Von-Willebrand-Disease

Investigation of the prevelance of endometriosis in patients with Von-Willebrand-Disease - Endometriose_VWS_Gyn

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025134

Enrollment

150

Registered

2022-01-21

Start date

2022-04-04

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N80 D68.00

Interventions

Group 1: Determination of the prevalence of Von-Willebrand-Disease in patients with endometriosis. Single blood collection (20 ml): determination of coagulation parameters. Data about a bleeding- or t

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: female patients, 18 years or older, signed form of consent, confirmed diagnosis of endometriosis

Exclusion criteria

Exclusion criteria: male patients, age <18 years, no signed form of consent, endometriosis not confirmed

Design outcomes

Primary

Measure	Time frame
Diagnosis of Von-Willebrand-Disease based on secondary outcome (measurements and results of questionnaire)	—

Secondary

Measure	Time frame
Single blood sample (max. 20 ml): Determination of VWF-Ag, VWF-RCo, Ratio VWF-RCo/VWF-Ag, PFA Collagen/Epinephrine, Factor VIII-Activity, Thrombin Time, Prothrombin Time, aPTT, CA125 in serum; patient survey about different hemostaseological/gynecological parameters through a questionnaire: bleeding/case history of thrombosis, bleeding-signs, surgeries (type, complications), anemia, thrombosis/embolism, infarction, family case-history regarding bleeding/thrombosis, gynecological case-history, medication; determination of ISTH BAT (Bleeding Assessment Tool) Score (Rodeghiero et al., 2010) based; additional data collection: age, initial diagnosis of endometriosis, therapy, symptoms, surgeries, method of contraception, acute/recent infections, cancerous diseases, known coagulation-disorder	—

Measure

Time frame

Single blood sample (max. 20 ml): Determination of VWF-Ag, VWF-RCo, Ratio VWF-RCo/VWF-Ag, PFA Collagen/Epinephrine, Factor VIII-Activity, Thrombin Time, Prothrombin Time, aPTT, CA125 in serum; patient survey about different hemostaseological/gynecological parameters through a questionnaire: bleeding/case history of thrombosis, bleeding-signs, surgeries (type, complications), anemia, thrombosis/embolism, infarction, family case-history regarding bleeding/thrombosis, gynecological case-history, medication; determination of ISTH BAT (Bleeding Assessment Tool) Score (Rodeghiero et al., 2010) based; additional data collection: age, initial diagnosis of endometriosis, therapy, symptoms, surgeries, method of contraception, acute/recent infections, cancerous diseases, known coagulation-disorder

—

Countries

Germany

Contacts

Public ContactWolfgang Miesbach

Hämophiliezentrum, Institut für Transfusionsmedizin, Medizinische Klinik III, Goethe Universitätsklinikum

wolfgang.miesbach@kgu.de06963015051

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026